1. Pink Sheet
  2. >>Product Reviews

Keeping Track: Ilumya, Adcetris Approved; Xtandi Priority Reviewed; Azedra Goal Date Extended

 
• By Michael Cipriano and Bridget Silverman

The latest drug development news and highlights from our US FDA Performance Tracker.

Keeping Track Feature image

A few big approvals stole the spotlight at the US FDA last week, including Sun Pharmaceutical Industries Ltd.'spsoriasis treatment Ilumya (tildrakizumab-asmn), which became the second biologic approved by the Center for Drug Evaluation and Research (CDER) and the sixth overall CDER-approved novel agent in 2018. It was also the first standard review novel approval of 2018.

Sharing the podium with Ilumya was Seattle Genetics Inc.'s Adcetris (brentuximab vedotin)‎, which scored a supplemental indication for the...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Product Reviews

More from Pink Sheet

Recent And Upcoming FDA Advisory Committee Meetings

 
• By Sue Sutter

Recent and upcoming US FDA advisory committee meetings and a summary of the topics covered.

UK-Wide Strategy Needed To Move Clinical Trial Diversity Plans To Next Stage

 
• By Vibha Sharma

The UK’s research-based pharma industry and medical research charities have set out clear action points to drive greater diversity and inclusion in clinical trials.

Blenrep’s Comeback Continues As England Becomes First To Fund Drug

 
• By Eliza Slawther

Blenrep, GSK’s multiple myeloma therapy, faced a major setback when it was withdrawn from the market in 2022. The drug has since made a return as a second-line therapy, and is on track to being reimbursed in England.